GANITE
LOE Approachinggallium nitrate
NDAINJECTIONINJECTABLEPriority Review
Approved
Jan 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANITE (gallium nitrate) is an intravenous injectable approved in 1991 for the treatment of hypercalcemia of malignancy. The mechanism of action involves inhibition of osteoclast-mediated bone resorption, reducing serum calcium levels in cancer patients with life-threatening hypercalcemic episodes.
LOE Approaching
As LOE approaches with moderate competitive pressure (30%), the brand team is likely in defensive/transition mode with reduced investment and smaller commercial headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GANITE offers limited career upside; with zero linked job openings and an LOE-approaching lifecycle, this is a maintenance product requiring primarily defensive sales and managed decline execution. Career growth is constrained, making it better suited for short-term, tactical roles rather than long-term advancement.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.